Holocene Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Holocene Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$668K	Hold	11,679	–	–	﹤0.01%	717
2026 Q1	$660K	Hold	11,679	–	–	﹤0.01%	710
2025 Q4	$694K	Buy	11,679 +6,281	+116%	+$342K	﹤0.01%	642
2025 Q3	$292K	Sell	5,398 -3,072	-36%	-$176K	﹤0.01%	714
2025 Q2	$466K	Hold	8,470	–	–	﹤0.01%	705
2025 Q1	$599K	Buy	+8,470	New	+$570K	﹤0.01%	662
2024 Q4	–	Sell	-563,476	Closed	-$39.6M	–	763
2024 Q3	$39.6M	Sell	563,476 -149,628	-21%	-$12.5M	0.16%	172
2024 Q2	$58.7M	Buy	713,104 +517,108	+264%	+$43M	0.25%	125
2024 Q1	$17.1M	Buy	+195,996	New	+$17.5M	0.06%	224
2018 Q2	–	Sell	-3,139	Closed	-$254K	–	584
2018 Q1	$254K	Sell	3,139 -8,074	-72%	-$693K	0.01%	433
2017 Q4	$1M	Buy	+11,213	New	+$975K	0.03%	129

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Holocene Advisors's BMRN Position: Q2 2026 in Review

Holocene Advisors held its BioMarin Pharmaceuticals (BMRN) position steady in Q2 2026 at 11,679 shares worth $668K. The position accounts for ﹤0.01% of the portfolio, ranked #717.

Holocene Advisors first reported a position in BMRN in Q4 2017 and has held it in 11 quarters since. The position peaked at $58.7M in Q2 2024. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Holocene Advisors held 11,679 shares of BioMarin Pharmaceuticals worth $668K as of Q2 2026.
Holocene Advisors left its BioMarin Pharmaceuticals share count unchanged in Q2 2026.
BioMarin Pharmaceuticals made up ﹤0.01% of Holocene Advisors's portfolio in Q2 2026, its #717 holding.
Holocene Advisors first reported a position in BioMarin Pharmaceuticals in Q4 2017 and has held it in 11 quarters since.
Holocene Advisors's BioMarin Pharmaceuticals position peaked at $58.7M in Q2 2024.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Holocene Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.